InVivo Therapeutics Holdings Corp. (NVIV) today announced the
appointment of Steven McAllister as Interim Chief Financial Officer,
effective December 31, 2013. He replaces Gregory Perry, who, as
previously announced, will leave December 30, 2013 to join another local
biotechnology company as its Chief Financial and Business Officer.
Mr. McAllister served as Vice President, Finance and Administration for
Biomet Spine and Bone Healing Technologies from 2007 – 2013. From 1999 –
2007 he served in several capacities, including Director of Finance,
Worldwide Operations, for Depuy Inc, and from 1984 – 1999 he worked in
several capacities at Howmedica, a Pfizer subsidiary that was sold to
Stryker in 1998.
Michael Astrue, InVivo’s Interim Chief Executive Officer, said, "Steve
McAllister brings expertise in both finance and in the operations of
device companies. I am confident that he will provide the same judgment,
integrity and strategic vision provided by Greg Perry during our initial
repositioning of InVivo.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company
with unique technologies for drug delivery with a focus on treatment of
spinal cord injuries. The Company was founded in 2005 with proprietary
technology co-invented by Robert Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
is affiliated with Massachusetts General Hospital. In 2011 the Company
earned the David S. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury
medicine. The publicly traded company is headquartered in Cambridge, MA.
For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. Any forward-looking statements
contained herein are based on current expectations, but are subject to a
number of risks and uncertainties, and include statements regarding the
Company’s expectations with respect to the commencement of human
clinical trials for the scaffold product, the timing of the submission
of its revised protocol to the FDA, the impact that the revised protocol
would have on the progress of the clinical trials, the impact of the
Company’s efforts with respect to the manufacturing of the scaffolds and
possible partnerships for its hydrogel product. The factors that could
cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties
relating to the Company’s ability to obtain FDA approval of its revised
protocol and the timing thereof; the identification of appropriate
clinical sites; the Institutional Review Board process; the Company’s
ability to enter into partnerships; the Company’s ability to obtain FDA
approval to commercialize its products; the Company’s ability to
develop, market and sell products based on its technology; the expected
benefits and efficacy of the Company’s products and technology in
connection with spinal cord injuries; the availability of substantial
additional funding for the Company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the Company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in our filings with the SEC, including our Form 10-K and 10-Qs
and our current reports on Form 8-K. We do not undertake to update these
forward-looking statements made by us.
Copyright Business Wire 2013